Next Article in Journal
Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects
Previous Article in Journal
Prenatal Screening Using Maternal Markers
Previous Article in Special Issue
Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice
Open AccessReview

Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives

Department of Medical Oncology, Institut Curie, 26 Rue d'Ulm, Paris 75005, France
*
Author to whom correspondence should be addressed.
J. Clin. Med. 2014, 3(2), 521-536; https://doi.org/10.3390/jcm3020521
Received: 2 February 2014 / Revised: 3 March 2014 / Accepted: 14 March 2014 / Published: 9 May 2014
(This article belongs to the Special Issue Prevention and Treatment of Bone Metastases from Breast Cancer)
One in four breast cancer patients is at risk of developing bone metastases in her life time. The early prevention of bone metastases is a crucial challenge. It has been suggested that the use of zoledronic acid (ZOL) in the adjuvant setting may reduce the persistence of disseminated tumor cells and thereby might improve outcome, specifically in a population of patients with a low estrogen microenvironment. More recently, the results of a large meta-analysis from 41 randomized trials comparing a bisphosphonate (BP) to placebo or to an open control have been presented at the 2013 San Antonio Breast Cancer Meeting. Data on 17,016 patients confirm that adjuvant BPs, irrespective of the type of treatment or the treatment schedule and formulation (oral or intra-venously (IV)), significantly reduced bone recurrences and improved breast cancer survival in postmenopausal women. No advantage was seen in premenopausal women. BPs are soon likely to become integrated into standard practice. Published data on the mechanisms involved in tumor cell seeding from the primary site, in homing to bone tissues and in the reactivation of dormant tumor cells will be reviewed; these might offer new ideas for innovative combination strategies. View Full-Text
Keywords: breast cancer; bone metastasis; adjuvant treatment; neoadjuvant treatment; bisphosphonates; zoledronic acid; denosumab; osteonecrosis of the jaw breast cancer; bone metastasis; adjuvant treatment; neoadjuvant treatment; bisphosphonates; zoledronic acid; denosumab; osteonecrosis of the jaw
MDPI and ACS Style

Beuzeboc, P.; Scholl, S. Prevention of Bone Metastases in Breast Cancer Patients. Therapeutic Perspectives. J. Clin. Med. 2014, 3, 521-536.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop